US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
US provider of chemical biology technologies Totus Medicines has announced the appointment of Nassim Usman as president and chief executive. 16 December 2023
Former Novartis executive James Bradner has joined Amgen as executive vice president of research and development (R&D), and chief scientific officer. 14 December 2023
Californian antibody specialist Electra Therapeutics has appointed Kathy Dong as president and chief executive, replacing current CEO Adam Rosenthal. 13 December 2023
US mRNA medicines company Moderna has announced changes to its operating model to bring focus to its short- and long-term business goals. 13 December 2023
Singapore-based clinical-stage biotech Hummingbird Bioscience today announced the appointment of Angèle Maki, as chief business officer (CBO), with immediate effect. 11 December 2023
Massachusetts, USA-based cell therapy specialist Abcuro today announced the appointment of Mark Pruzanski as chairman of its board of directors. 6 December 2023
Germany-based Thermosome, a drug development company specializing in targeted tumor therapies, has named Frank Hermann as chief medical officer (CMO). 5 December 2023
Inflammation and immunology (I&I) specialist Zenas BioPharma has named Jennifer Fox as its chief business officer and chief financial officer and Tanya Fischer as head of research and development and chief medical officer. 4 December 2023
Swiss clinical-stage biotech AC Immune today announced the appointment, effective January, 2024, of Dr Madiha Derouazi as chief scientific officer. 1 December 2023
British biotech Levicept has appointed Eliot Forster as chief executive, with the company’s founder, Simon Westbrook, taking up the role of chief scientific officer. 30 November 2023
Belgian biotech Agomab Therapeutics today announced the appointment of Dr Angelika Jahreis as an independent non-executive director to its board of directors, while Andrea Sáez will join Agomab’s executive leadership team as chief development officer. 29 November 2023
US biotech Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, has announced changes to its executive leadership team. 24 November 2023
Utah, USA-based biotech Halia Therapeutics has appointed Lisa Shamon as vice president of regulatory affairs and Xianne Penny as a senior medical director. 17 November 2023
UK-based eXmoor pharma, a cell and gene therapy (CGT) manufacturing partner, has announced the hiring of Matthew Paterson as the company’s first chief commercial officer. 15 November 2023
Cambridge, USA-based precision oncology firm Incendia Therapeutics today announced the appointment of Dr Wendye Robbins as chief executive (CEO). 13 November 2023